product name Prazosin HCl
Description: Prazosin HCl (also known as cp-12299-1) is a competitive alpha-1 adrenoceptor antagonist, used to treat high blood pressure or benign prostatic hyperplasia. Prazosin leads to a significant increase in VEGF concentration in endothelial cells and angiogenesis only if eNOS is present. Prazosin binds to the α1-adrenergic receptors that are present on smooth muscle cells surrounding all larger blood vessels.
References: Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2300-8; Psychopharmacology (Berl). 2011 Nov;218(1):89-99.
419.86
Formula
C19H21N5O4·HCl
CAS No.
19237-84-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 4 mg/mL (9.52 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
cp-12299-1
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19398613
| In Vitro |
In vitro activity: Prazosin leads to a significant increase in VEGF concentration in endothelial cells and angiogenesis only if eNOS is present. Prazosin binds to the α1-adrenergic receptors that are present on smooth muscle cells surrounding all larger blood vessels. Prazosin (0.1 nM) blocks the increases in perfusion pressure caused by electrical stimulation of the perimesenteric nerves but does not significantly reduce the vasomotor effect of exogenous noradrenaline. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Prazosin application leads to the expansion of the capillary system by modulation of the hemodynamic environment (flow rate, shear stress) in skeletal muscle. Prazosin induces angiogenesis in extensor digitorum longus (EDL) muscles of C57BL/6 mice but not eNOS-knockout mice. Prazosin (0.5-2.0 mg/kg) blocks Yohimbine-induced reinstatement of food and alcohol seeking, as well as footshock-induced reinstatement of alcohol seeking in rats. Prazosin (0.2mg kg(-1) s.c.) causes an enhancement of a suppression of conditioned avoidance response in the presence of the dopamine D2 receptor antagonist raclopride (0.05-0.20 mg/kg s.c.) in rats. Prazosin administration alone (1 mg/kg, s.c.) only slightly reduces horizontal activity during an initial 10 min measurement period, although it consistently reduces rearing in freely moving rats. Prazosin effectively suppresses the locomotor stimulation caused by either dose of MK-801 throughout the whole observation period in freely moving rats. |
| Animal model | |
| Formulation & Dosage | |
| References | Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2300-8; Psychopharmacology (Berl). 2011 Nov;218(1):89-99. |
Related Posts
product name Prazosin HCl
Description: Prazosin HCl (also known as cp-12299-1) is a competitive alpha-1 adrenoceptor antagonist, used to treat high blood pressure or benign prostatic hyperplasia. Prazosin leads to a significant increase in VEGF concentration in endothelial cells and angiogenesis only if eNOS is present. Prazosin binds to the α1-adrenergic receptors that are present on smooth muscle cells surrounding all larger blood vessels.
References: Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2300-8; Psychopharmacology (Berl). 2011 Nov;218(1):89-99.
419.86
Formula
C19H21N5O4·HCl
CAS No.
19237-84-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 4 mg/mL (9.52 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
cp-12299-1
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19398613
| In Vitro |
In vitro activity: Prazosin leads to a significant increase in VEGF concentration in endothelial cells and angiogenesis only if eNOS is present. Prazosin binds to the α1-adrenergic receptors that are present on smooth muscle cells surrounding all larger blood vessels. Prazosin (0.1 nM) blocks the increases in perfusion pressure caused by electrical stimulation of the perimesenteric nerves but does not significantly reduce the vasomotor effect of exogenous noradrenaline. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Prazosin application leads to the expansion of the capillary system by modulation of the hemodynamic environment (flow rate, shear stress) in skeletal muscle. Prazosin induces angiogenesis in extensor digitorum longus (EDL) muscles of C57BL/6 mice but not eNOS-knockout mice. Prazosin (0.5-2.0 mg/kg) blocks Yohimbine-induced reinstatement of food and alcohol seeking, as well as footshock-induced reinstatement of alcohol seeking in rats. Prazosin (0.2mg kg(-1) s.c.) causes an enhancement of a suppression of conditioned avoidance response in the presence of the dopamine D2 receptor antagonist raclopride (0.05-0.20 mg/kg s.c.) in rats. Prazosin administration alone (1 mg/kg, s.c.) only slightly reduces horizontal activity during an initial 10 min measurement period, although it consistently reduces rearing in freely moving rats. Prazosin effectively suppresses the locomotor stimulation caused by either dose of MK-801 throughout the whole observation period in freely moving rats. |
| Animal model | |
| Formulation & Dosage | |
| References | Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2300-8; Psychopharmacology (Berl). 2011 Nov;218(1):89-99. |